Explore the effectiveness and safety results, learn about dosing and self-injection with the prefilled syringe, and find much more in this informative brochure.
Doctor discussion guide
The CIDP Doctor Discussion Guide is a helpful tool for navigating your treatment journey. Use it to guide conversations with your doctor so they can help determine if VYVGART Hytrulo is right for you.
Self-injection guide
Reference this step-by-step guide to help understand how to self-inject with the VYVGART Hytrulo prefilled syringe. Always reference the Instructions for Use for complete guidance.
Self-injection FAQ sheet
Here’s what you need to know about the VYVGART Hytrulo prefilled syringe for self-injection.
In-office subcutaneous injection guide
VYVGART Hytrulo is still available as an injection from your healthcare provider. Get information about dosing and how to prepare for your VYVGART Hytrulo subcutaneous injection.
Insurance and coverage guide
Gain a better understanding of the insurance process and learn how the team at My VYVGART Path may assist you in accessing VYVGART Hytrulo.
My VYVGART Path brochure
Learn more about My VYVGART Path, the patient support program that has friendly and knowledgeable Nurse Case Managers to support you on your VYVGART Hytrulo treatment journey.
Patient Co-pay Program brochure
See if you could be eligible to pay as little as $0 for your co-pay through the VYVGART Hytrulo Co-pay Program.a
a Eligible commercially insured patients may pay as little as $0 for VYVGART Hytrulo and may receive a maximum benefit of $25,000 per calendar year for their eligible out-of-pocket costs for the drug and drug administration. Persons residing in MA and RI are not eligible for financial assistance related to administration costs. Please see full Terms and Conditions.
Patient enrollment form
Already have a VYVGART Hytrulo prescription? Fill out the enrollment form to join the My VYVGART Path Patient Support Program.
Guide for caregivers
Explore caregiver-specific education about VYVGART Hytrulo, self-care tips, and resources.
Patient emergency contact card
Use this card to share treatment information and key contacts in case of emergency.
Other helpful VYVGART Hytrulo information
Breaking Through Today
This milestone virtual event explored VYVGART Hytrulo, the first major innovation in CIDP treatment in over 30 years.*
*VYVGART Hytrulo contains efgartigimod alfa and hyaluronidase, and is specifically designed to attach to FcRn receptors.
FcRn=neonatal Fc receptor.
Frequently asked questions
Find answers to common questions about VYVGART Hytrulo treatment and support.
Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.
Before taking VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:
- have an infection or fever.
- have recently received or are scheduled to receive any vaccinations.
- have any history of allergic reactions.
- have kidney (renal) problems.
- are pregnant or plan to become pregnant. It is not known whether VYVGART HYTRULO will harm your unborn baby.
- Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com
- are breastfeeding or plan to breastfeed. It is not known if VYVGART HYTRULO passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
VYVGART HYTRULO can cause side effects which can be serious, including:
- Infection. VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection:
- fever
- chills
- frequent and painful urination
- cough
- pain and blockage of nasal passages
- wheezing
- shortness of breath
- sore throat
- excess phlegm
- nasal discharge
- Allergic reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction:
- rash
- swelling of the face, lips, throat, or tongue
- shortness of breath
- hives
- trouble breathing
- low blood pressure
- fainting
- Infusion or injection-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction:
- high blood pressure
- chills
- shivering
- chest, stomach, or back pain
The most common side effects of VYVGART HYTRULO include respiratory tract infection, headache, urinary tract infection, and injection site reactions.
These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc)?
VYVGART HYTRULO is a prescription medicine used to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
It is not known if VYVGART HYTRULO is safe and effective in children.
Please see full Prescribing and Patient Information for VYVGART HYTRULO.
Dosage forms and strengths:
VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial.
IMPORTANT SAFETY INFORMATION
Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.
Before taking VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:
- have an infection or fever.
- have recently received or are scheduled to receive any vaccinations.
- have any history of allergic reactions.
- have kidney (renal) problems.
- are pregnant or plan to become pregnant. It is not known whether VYVGART HYTRULO will harm your unborn baby.
- Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com
- are breastfeeding or plan to breastfeed. It is not known if VYVGART HYTRULO passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
VYVGART HYTRULO can cause side effects which can be serious, including:
- Infection. VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection:
- fever
- chills
- frequent and painful urination
- cough
- pain and blockage of nasal passages
- wheezing
- shortness of breath
- sore throat
- excess phlegm
- nasal discharge
- Allergic reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction:
- rash
- swelling of the face, lips, throat, or tongue
- shortness of breath
- hives
- trouble breathing
- low blood pressure
- fainting
- Infusion or injection-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction:
- high blood pressure
- chills
- shivering
- chest, stomach, or back pain
The most common side effects of VYVGART HYTRULO include respiratory tract infection, headache, urinary tract infection, and injection site reactions.
These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc)?
VYVGART HYTRULO is a prescription medicine used to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
It is not known if VYVGART HYTRULO is safe and effective in children.
Please see full Prescribing and Patient Information for VYVGART HYTRULO.
Dosage forms and strengths:
VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial.
Facebook
Twitter
PinterestThis site is intended for patients and caregivers.
Disclaimer | Privacy Policy | Contact Us |
VYVGART and VYVGART Hytrulo are registered trademarks of argenx.
LIVE VYVIDLY and THAT’S LIVING VYVIDLY are trademarks of argenx.
For U.S. audiences only.
©2025 argenx
US-VYV_HYT-24-00526 V2 05/2025
